

***Remarks***

Claims 2, 15, 17, 19 and 21 are pending in the application. Claims 1 and 15 are allowed. Claims 17, 19 and 21 are rejected under 35 U.S.C. § 112, 1<sup>st</sup> paragraph (written description and enablement) and 35 U.S.C. 103(a). In order to expedite prosecution, Applicants hereby cancel Claims 17, 19 and 22 while reserving the right to prosecute these claims in a continuing application.

***Conclusions***

In view of the foregoing amendments and remarks, Applicants respectfully submit that Claims 2 and 15 set forth an invention that is new, useful, and unobvious, and which is therefore deserving of patent protection. Passage to Issue of the present application is believed to be in order, and is respectfully requested.

Please charge any fees or credit any overpayment in connection with this application which may be required by this or any related paper to Deposit Account No. 05-0840.

If the Examiner has any questions, or would like to discuss any matters in connection with this application, he or she is invited to contact the undersigned at (317) 276-0307.

Respectfully submitted,

/John A. Cleveland, Jr., Ph.D./

John A. Cleveland, Jr., Ph.D.  
Attorney for Applicants  
Registration No. 50,697  
Phone: 317-276-0307

Eli Lilly and Company  
Patent Division/  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
April 11, 2007